Lung Cancer Clinical Trial
Official title:
Surgical Treatment Of Stage IIIB Non-Small Cell Lung Cancer After Induction-Chemoradiotherapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing
so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor
cells. Combining chemotherapy with radiation therapy may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining chemotherapy and radiation
therapy before surgery in treating patients who have stage IIIB non-small cell lung cancer.
Status | Terminated |
Enrollment | 5 |
Est. completion date | |
Est. primary completion date | October 2002 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 75 Years |
Eligibility |
DISEASE CHARACTERISTICS: - Histologically or cytologically confirmed primary stage IIIB non-small cell lung cancer (NSCLC) - T4, any N, M0 or any T, N3, M0 - No N3 disease due to scalene or supraclavicular lymph node involvement - No primary tumors located in the lower lobe combined with contralateral upper higher mediastinal lymph node involvement - No mixed tumor types with small cell lung cancer - At least 1 unidimensionally measurable target lesion - At least 20 mm by conventional techniques OR - At least 10 mm by spiral CT scan - No pre-existing pleural or pericardial effusion - No CNS involvement by CT scan or MRI PATIENT CHARACTERISTICS: Age: - 18 to 75 Performance status: - WHO 0-1 Life expectancy: - Not specified Hematopoietic: - Absolute neutrophil count at least 2,000/mm^3 - Platelet count at least 100,000/mm ^3 Hepatic: - Bilirubin no greater than 1.5 times upper limit of normal (ULN) - AST/ALT no greater than 1.5 times ULN - Alkaline phosphatase no greater than 2.5 times ULN Renal: - Creatinine no greater than 1.25 times ULN - Creatinine clearance at least 60 mL/min Cardiovascular: - No clinical evidence of superior vena cava syndrome Pulmonary: - Postoperative FEV1 and KCO greater than 40% predicted - VO2 max greater than 15 mL/min/kg (if postoperative KCO no greater than 40% predicted) Other: - No other primary malignancy except carcinoma in situ of the cervix, adequately treated basal cell skin cancer, or other malignancy treated more than 5 years ago without recurrence (excluding melanoma, breast cancer, or hypernephroma) - No active uncontrolled infection requiring IV antibiotics - No pre-existing sensory neurotoxicity grade 2 or greater - No psychological, familial, sociological, or geographical condition that would preclude study compliance - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: - No prior immunotherapy for NSCLC - No concurrent immunotherapy during induction chemoradiotherapy - Concurrent colony stimulating factors allowed Chemotherapy: - No prior chemotherapy for NSCLC Endocrine therapy: - No concurrent anticancer hormonal agents (except corticosteroids for antiemetic prophylaxis) during induction chemoradiotherapy Radiotherapy: - No prior radiotherapy for NSCLC Surgery: - No prior surgery for NSCLC Other: - No other concurrent anticancer drugs during induction chemoradiotherapy |
Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Belgium | Algemeen Ziekenhuis Middelheim | Antwerp | |
Belgium | Universitair Ziekenhuis Antwerpen | Edegem | |
Germany | Thoraxklinik Rohrbach | Heidelberg | |
Netherlands | Gelre Ziekenhuizen - Lokatie Lukas | Apeldoorn | |
Netherlands | Sint Antonius Ziekenhuis | Nieuwegein | |
Netherlands | Rotterdam Cancer Institute | Rotterdam | |
Netherlands | University Hospital - Rotterdam Dijkzigt | Rotterdam | |
Netherlands | Academisch Ziekenhuis Utrecht | Utrecht | |
Poland | Medical University of Gdansk | Gdansk | |
Poland | National Institute of Tuberculosis and Lung Diseases | Warsaw |
Lead Sponsor | Collaborator |
---|---|
European Organisation for Research and Treatment of Cancer - EORTC |
Belgium, Germany, Netherlands, Poland,
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|